Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- Retatrutide (GLP-3R) produces a favorable fat-to-lean loss ratio within the incretin class, with most weight loss coming from fat.1
- Lean-mass loss affects insulin sensitivity, resting metabolic rate, and mobility, especially in older adults and people with type 2 diabetes.
- Preserving muscle requires 1.6–2.2 g/kg/day protein plus 2–3 weekly resistance-training sessions; protein intake alone does not protect lean mass.
- DEXA scans every 3–6 months, BIA every 4–6 weeks, and functional strength tests together give a clear picture of body-composition change.
- Retatrutide remains investigational and affects cardiovascular function, so physician supervision is essential. You can schedule a consultation with our team to design a personalized, medically supervised protocol.
Methodology: How This Report Was Compiled
The evidence base for this report draws from peer-reviewed Phase 2 clinical trials of retatrutide published in the New England Journal of Medicine (Jastreboff et al., 2023) and The Lancet Diabetes & Endocrinology (Coskun et al., 2025), the STEP-1 DEXA substudy for semaglutide (Wilding et al., NEJM, 2021), the SURMOUNT-1 DEXA substudy for tirzepatide (Look et al., 2025), and 2025–2026 multi-society nutrition advisory guidelines. Retatrutide remains investigational and is not FDA-approved as of September 2026, with Phase 3 TRIUMPH data still emerging. Clear disclosure of this status supports the credibility of this report.
Key Finding 1: The Fat-to-Lean Loss Ratio in GLP-3R Clinical Trials
The only published retatrutide body-composition data come from a Phase 2 DEXA substudy in type 2 diabetes (Coskun et al., Lancet Diabetes & Endocrinology, August 2025; 189 enrolled, 103 with both scans). At week 36, fat mass fell by up to 26.1% at the 8 mg dose, and the authors concluded that “the proportion of lean mass loss to weight loss was similar to other obesity treatments.”1 At the 12 mg dose over 48 weeks, approximately three quarters of weight lost was fat mass, with the remaining share attributable to lean-mass reduction.1
Comparator data provide important context. In the SURMOUNT-1 DEXA substudy of tirzepatide (Look et al., Diabetes, Obesity and Metabolism, 2025; n=160), roughly 25% of weight lost was lean mass.1 In STEP-1 with semaglutide 2.4 mg, approximately 39% of weight lost was lean mass after 68 weeks, a higher proportion than reported with retatrutide.1 Retatrutide therefore sits at the favorable end of the incretin class for fat-to-lean loss ratio, although absolute lean-mass loss can be higher because total weight loss is greater.1
| Trial (Agent) | Total Weight Loss | Lean Mass Share of Loss | Fat Mass Share of Loss |
|---|---|---|---|
| Phase 2 DEXA substudy — retatrutide 12 mg (Coskun et al., 2025) | ~24% at 48 weeks | ~20–26% | ~74–80% |
| SURMOUNT-1 — tirzepatide (Look et al., 2025) | ~21.3% at 72 weeks | ~25% | ~75% |
| STEP-1 — semaglutide 2.4 mg (Wilding et al., 2021) | ~14.9% at 68 weeks | ~30–39% | ~61–70% |
Note: Cross-trial comparisons are indirect. No head-to-head trials exist, and data come from separate populations and DEXA protocols.
Researchers have proposed that retatrutide’s glucagon receptor component might preserve muscle better than single- or dual-agonists. Current data, however, support parity with other agents rather than clear superiority.
This lean-mass loss, while proportionally favorable, still carries consequences, so understanding its metabolic impact remains critical.
Key Finding 2: Why Lean Mass Loss Matters Beyond Aesthetics
A 2026 commentary by Imaizumi and Yabe in the Journal of Diabetes Investigation states that the “next challenge in the incretin era is not simply greater weight loss, but healthier weight loss.” The metabolic and functional consequences of lean-mass loss during rapid weight reduction are substantial. Muscle accounts for approximately 80% of insulin-stimulated glucose uptake, and each kilogram of lean mass contributes meaningfully to resting metabolic rate. Lean-mass loss also compromises mobility and independence, which is especially concerning for adults over 60 who face anabolic resistance.
Older adults with type 2 diabetes are particularly vulnerable, as sarcopenia is associated with insulin resistance, falls, fractures, disability, and mortality. DEXA-measured “lean mass” includes organ tissue, connective tissue, and water, not only contractile muscle, so the clinical impact of a lean-mass share in the 20–26% range depends heavily on the person’s starting muscle reserve. Older adults, those with type 2 diabetes, and individuals with sarcopenic obesity carry the highest risk.
Key Finding 3: What the Evidence Says About Protein and Resistance Training
The 2025 multi-society joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society recommends 1.2–2.0 g/kg/day of protein during active GLP-1–assisted weight loss, using adjusted body weight for individuals with obesity. A 2025 Endocrine Society study found that higher protein intake directly correlated with less muscle loss in GLP-1 users, with a minimum effective threshold of 1.2 g/kg/day and an optimal range up to 1.6 g/kg/day.
Protein alone, however, is insufficient; resistance training forms the other half of the equation. For resistance training, the 2025 systematic review by McMath and Gallagher (Columbia University) in Obesity Reviews and a 2021 Sports Medicine meta-analysis (22 RCTs, n=1,012) showing that resistance training during caloric restriction preserved an additional 0.81 kg of lean mass versus diet alone both support structured training as a core intervention. The 2025 Joint Advisory explicitly notes that increased protein intake alone is unlikely to preserve muscle mass without structured resistance or strength training.
The Physician-Supervised Muscle Preservation Protocol: 5 Evidence-Based Steps
Step 1: Calculate and Distribute Your Protein Target
Retatrutide’s profound appetite suppression can reduce spontaneous protein intake below therapeutic thresholds, so an explicit target of 1.6–2.2 g/kg of adjusted body weight daily is necessary. This range aligns with evidence-based recommendations for caloric restriction with resistance training, and older adults should aim for 2.0–2.4 g/kg/day to counter anabolic resistance.
| Body Weight (lbs) | Protein at 1.6 g/kg (g/day) | Protein at 2.0 g/kg (g/day) |
|---|---|---|
| 150 lbs (68 kg) | 109 g | 136 g |
| 200 lbs (91 kg) | 145 g | 182 g |
| 250 lbs (113 kg) | 181 g | 226 g |
Mamerow et al. (2014) showed that even distribution of protein across meals increased 24-hour muscle protein synthesis by 25% versus skewed patterns. Distribute intake across 3–4 meals at 30–40 g per sitting, and prioritize high-leucine sources such as whey, chicken breast, Greek yogurt, eggs, and salmon.
Step 2: Structure Resistance Training for Muscle Retention
The recommended minimum effective dose is two to three weekly sessions of full-body compound movements, such as squats, deadlifts, presses, and rows, performed at 6–15 repetitions with 1–3 repetitions in reserve. A landmark 2025 study in Frontiers in Endocrinology found that resistance training was the only exercise modality that consistently preserved fat-free mass during weight loss. In that study, 85% of resistance-trained participants gained lean mass, while 50% of aerobic-only participants lost fat-free mass.
A simple weekly schedule could include Monday for full body, Wednesday for upper body focus, and Friday for lower body focus. The ACSM position stand on resistance training recommends progressive overload: once a patient can complete two repetitions beyond the target range on two consecutive sessions, increase load by 2–5% for upper-body exercises and 5–10% for lower-body exercises.
Step 3: Monitor Body Composition, Not Just Scale Weight
The scale cannot distinguish fat from muscle, so body-composition tracking is essential. DEXA is the reference standard, with a baseline scan before starting GLP-3R and repeat scans every 3–6 months. DEXA precision error is within 1.6 kg for fat-free mass, so changes smaller than approximately 0.5–0.8 kg may fall within measurement noise. This makes DEXA best suited for longer-interval trend assessment rather than frequent short-interval decisions.
For interim tracking between DEXA scans, research-grade multi-frequency BIA every 4–6 weeks under standardized conditions provides a practical complement. Use the same time of day, arrive fasted and hydrated, and avoid exercise for 12 hours beforehand. The 2026 Pharmaceuticals review by Sancho-Haro et al. supports tracking functional metrics such as handgrip strength and chair-stand performance alongside structural measures as part of a multidimensional monitoring framework during GLP-1-based weight-loss therapy.
Step 4: Address Cardiovascular Monitoring
In the Phase 2 randomized double-blind trial (NEJM 2023), the 12 mg dose of retatrutide produced a peak heart-rate increase of +9.9 bpm at week 24, declining to +5.2 bpm by week 48, alongside a systolic blood-pressure reduction of −12.7 mmHg and diastolic reduction of −7.4 mmHg at week 48. This cardiovascular profile makes physician supervision essential.
Because retatrutide lowers blood pressure substantially, patients already on antihypertensive medication may need dose adjustments after starting therapy, and prescribers must direct any such changes. Dosing should be titrated slowly, starting at 2 mg rather than 4 mg to blunt transient tachycardic spikes. Patients should promptly report persistent resting heart rate above 100 bpm, palpitations, or dizziness.
Step 5: Engage Medical Supervision for Dosing and Adjustments
GLP-3R (retatrutide) is not FDA-approved, cannot be legally compounded, and products sold online lack quality verification for identity, purity, potency, and sterility. No clinical trial has yet studied retatrutide combined with structured resistance training and high-protein diets, so real-world protocols require a physician who can interpret emerging data, review labs, and adjust dosing. Mirror Plastic Surgery’s physician-led approach centers on this level of oversight.
Schedule your consultation with Ellie to begin a medically supervised GLP-3R protocol with comprehensive lab analysis and personalized dosing from Dr. Akash Chandawarkar.
About Mirror Plastic Surgery and Medical Supervision
Unsupervised peptide use carries concrete risks. Third-party batch testing is often absent, dosing can be incorrect, cardiovascular effects such as heart-rate elevation may go unmanaged, and muscle loss or metabolic changes may never be monitored. These outcomes are documented in settings where patients obtain investigational compounds outside a clinical framework.
Mirror Plastic Surgery follows a different model. Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained plastic surgeon with fellowship training at the Manhattan Eye Ear & Throat Hospital and medical innovation training at Stanford University, personally oversees every peptide protocol. Patients receive comprehensive lab analysis covering thyroid, liver, kidney, diabetes markers, and hormone panels. Dosing is personalized based on individual physiology and adjusted as weight loss progresses. Peptides are sourced from reputable providers with batch testing, and patients have 24/7 direct access to Dr. Chandawarkar via text throughout their protocol.
Start your muscle-preservation journey with Ellie and explore how physician-supervised GLP-3R protocols can support weight loss while protecting the muscle that keeps you strong and metabolically healthy.
Conclusion: The Evidence Supports a Deliberate Approach
GLP-3R (retatrutide) produces predominantly fat loss, with a favorable fat-to-lean loss ratio within the incretin class, yet lean-mass loss still occurs and requires active countermeasures. Protein intake in the 1.6–2.2 g/kg/day range, resistance training two to three times weekly, and regular DEXA-based monitoring form the core pillars of muscle preservation. Because retatrutide remains investigational, carries dose-dependent cardiovascular effects that require monitoring, and cannot be legally compounded in the United States, physician supervision remains essential.
The science continues to evolve, so the clinician interpreting that science plays a central role in safe and effective outcomes. Mirror Plastic Surgery offers a personalized, medically supervised approach that translates promising clinical data into practical, individually calibrated care.
Book your consultation with Ellie at Mirror Plastic Surgery to pursue transformative weight loss while preserving muscle.
This article is for informational purposes only and does not constitute medical advice. Results vary. Peptide therapies are not FDA-regulated and should only be used under professional supervision. Retatrutide (GLP-3R) is an investigational agent not approved by the FDA as of September 2026.
Frequently Asked Questions
What Does GLP-3R Do?
GLP-3R (retatrutide) activates GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation enhances insulin-mediated nutrient uptake and may support muscle protein preservation at the cellular level. Glucagon receptor activation increases energy expenditure through hepatic fat oxidation and thermogenesis. In Phase 2 trials, this triple mechanism produced up to 24.2% mean weight loss at 48 weeks, which was the largest reduction observed in any Phase 2 obesity trial at the time of publication.1 The glucagon component also drives preferential visceral fat mobilization, with android fat reduced by up to 31.4% at the 12 mg dose in the Phase 2 DEXA substudy.1
How Is GLP-3R Used?
Dosing must be individualized and medically supervised. Phase 3 protocols escalate from 2 mg weekly to 4 mg, 6 mg, 9 mg, and 12 mg at 4-week intervals between steps. Starting at 2 mg rather than 4 mg meaningfully reduces gastrointestinal side effects and blunts transient heart-rate spikes. Because retatrutide is investigational and not FDA-approved as of September 2026, it cannot be legally compounded in the United States. Products sold online as “retatrutide” are not manufactured under GMP conditions and carry serious risks related to unknown purity, potency, and sterility. Physician oversight, including baseline labs, ongoing monitoring, and dose adjustment, is essential for safe use.
Can You Regain Muscle on GLP-3R?
Muscle lost during treatment can be regained through “muscle memory,” which describes the capacity of previously trained muscle fibers to recover lean tissue more rapidly than untrained muscle. Many researchers report regaining lost lean tissue within 3–6 months of returning to maintenance calories while continuing resistance training. The most effective strategy, however, is to minimize loss from the start through the protein targets outlined in Step 1 and consistent resistance training two to three times weekly throughout the treatment period. Proactive preservation during active weight loss outperforms waiting until after treatment to address muscle loss.
Can a 70-Year-Old Regain Muscle Mass on GLP-3R?
Older adults can regain muscle mass on GLP-3R, but they face anabolic resistance, which means a reduced muscle protein synthesis response to the same protein stimulus. They therefore require higher protein targets, toward 2.0 g/kg/day, and structured resistance training to achieve similar preservation outcomes as younger adults. The 2025 Asian Working Group for Sarcopenia emphasizes that muscle health, not just weight, should be the therapeutic target in older adults and recommends BIA-based skeletal muscle index measurement as a primary screening tool. For adults over 60 on GLP-3R, slower dose escalation and more conservative weight-loss targets may also be appropriate to protect limited muscle reserve, making physician supervision especially critical.
What Is the Difference Between GLP-3R and GLP-1?
GLP-1 receptor agonists such as semaglutide activate a single receptor pathway, primarily reducing appetite and slowing gastric emptying. GLP-3R (retatrutide) activates three receptor pathways, GLP-1, GIP, and glucagon, which produces greater total weight loss and a different metabolic profile. The addition of GIP receptor agonism may support muscle protein preservation at the cellular level by activating pathways that suppress muscle protein degradation. The glucagon receptor component adds thermogenic energy expenditure and preferential visceral fat mobilization. The net result is greater total weight loss than GLP-1 monotherapy, with a lean-mass loss ratio that appears comparable to or slightly better than semaglutide, although no head-to-head trial has confirmed this directly.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
